Veteran investor Madhusudan Kela’s wife, Madhuri Madhusudan Kela, increased her holding in the underperforming small-cap drug company Kopran Ltd, purchasing more than five lakh shares in the quarter ended March 31, 2025. This has raised eyebrows in financial circles.
According to the latest shareholding disclosures, Madhuri Kela now holds 7.04 lakh equity shares in Kopran, translating to a 1.46% stake. This is an increase from the 1.04% stake (5 lakh shares) she held in the previous quarter ending December 2024. Based on the current stock price, her stake is now valued at over ₹12 crore.
Her acquisition came despite recent underperformance by the stock. On Wednesday, Kopran Ltd shares fell by more than 3%, closing at ₹175.45 apiece. Notably, markets remained closed on Thursday due to Mahavir Jayanti.
Kopran, headquartered in Mumbai, is an integrated pharmaceutical company with a global presence in formulations and Active Pharmaceutical Ingredients (APIs). Its manufacturing facilities have received approvals from key global regulatory authorities, which lends credibility to its product pipeline.
However, financial performance has not been encouraging. For the December 2024 quarter, the company’s revenue fell 12.6% year-on-year to ₹71.94 crore, while net profit declined nearly 13% to ₹7.41 crore.
The stock has seen a sharp correction over the past year, declining over 37%. That said, March 2025 brought a modest 4% uptick, breaking a five-month losing streak. Prior to this, the stock had slumped by 8% in February, 13.8% in January, 2.5% in December, 24.3% in November, and 13.3% in October.
Madhuri Kela first appeared in Kopran’s shareholder register in March 2023. As per SEBI norms, listed companies must disclose the names of shareholders holding 1% or more stake in each quarterly report.
Her recent move indicates a contrarian investment stance, backing a fundamentally significant company during a phase of depressed valuations.
Also Read: Check Your New EMI After RBI’s Repo Rate Cut
